Literature DB >> 3470952

Selection for phenylalanine hydroxylase activity in cells transformed with recombinant retroviruses.

F D Ledley, T Hahn, S L Woo.   

Abstract

Cells deficient in phenylalanine hydroxylase (PAH) are tyrosine auxotrophs and will not survive in tyrosine-free media. PAH activity can be constituted in cultured cells by infection with recombinant retroviruses carrying a human PAH cDNA. Mouse hepatoma cells transformed with recombinant PAH will grow in tyrosine-free media since these cells constitutively synthesize the cofactor tetrahydrobiopterin which is essential for PAH activity. NIH3T3 cells transformed with the PAH cDNA express the PAH apoenzyme, but this enzyme is inactive in vivo since these cells do not synthesize biopterin. We describe a method of selection for PAH in the fibroblast-like NIH3T3 cells involving tyrosine-free media supplemented with biopterin, reducing agents, and antioxidants. Cells transformed with the recombinant PAH gene exhibit PAH activity in culture and will grow in the biopterin-supplemented tyrosine-free media. Metabolic selection for PAH activity provides a new selectable marker for gene transfer experiments. This method is shown to be useful in the production of high titers of recombinant retroviruses carrying PAH and provides a model for experiments in somatic gene therapy of phenylketonuria.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3470952     DOI: 10.1007/BF01534694

Source DB:  PubMed          Journal:  Somat Cell Mol Genet        ISSN: 0740-7750


  12 in total

1.  Clinical application of somatic gene therapy in inborn errors of metabolism.

Authors:  F D Ledley
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

2.  Hepatocytes from wild-type or heterozygous donors are equally effective in achieving successful therapeutic liver repopulation in murine phenylketonuria (PKU).

Authors:  Kelly J Hamman; Shelley R Winn; Cary O Harding
Journal:  Mol Genet Metab       Date:  2011-08-04       Impact factor: 4.797

3.  Low therapeutic threshold for hepatocyte replacement in murine phenylketonuria.

Authors:  Kelly Hamman; Heather Clark; Eugenio Montini; Muhsen Al-Dhalimy; Markus Grompe; Milton Finegold; Cary O Harding
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

4.  Retroviral gene transfer into primary hepatocytes: implications for genetic therapy of liver-specific functions.

Authors:  F D Ledley; G J Darlington; T Hahn; S L Woo
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

5.  Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria.

Authors:  C O Harding; M B Gillingham; K Hamman; H Clark; E Goebel-Daghighi; A Bird; D D Koeberl
Journal:  Gene Ther       Date:  2006-03       Impact factor: 5.250

6.  Metabolic engineering as therapy for inborn errors of metabolism--development of mice with phenylalanine hydroxylase expression in muscle.

Authors:  C O Harding; K Wild; D Chang; A Messing; J A Wolff
Journal:  Gene Ther       Date:  1998-05       Impact factor: 5.250

7.  Retroviral-mediated gene transfer and expression of human phenylalanine hydroxylase in primary mouse hepatocytes.

Authors:  H Peng; D Armentano; L MacKenzie-Graham; R F Shen; G Darlington; F D Ledley; S L Woo
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

8.  Expression of phenylalanine hydroxylase (PAH) in erythrogenic bone marrow does not correct hyperphenylalaninemia in Pah(enu2) mice.

Authors:  Cary O Harding; Mark Neff; Kelly Jones; Krzysztof Wild; Jon A Wolff
Journal:  J Gene Med       Date:  2003-11       Impact factor: 4.565

9.  A novel Pah-exon1 deleted murine model of phenylalanine hydroxylase (PAH) deficiency.

Authors:  Daelyn Y Richards; Shelley R Winn; Sandra Dudley; Lev Fedorov; Nicole Rimann; Beat Thöny; Cary O Harding
Journal:  Mol Genet Metab       Date:  2020-09-30       Impact factor: 4.797

10.  Pahhph-5: a mouse mutant deficient in phenylalanine hydroxylase.

Authors:  J D McDonald; V C Bode; W F Dove; A Shedlovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.